hematopoiet
stem
cell
transplant
hsct
establish
form
therapi
number
malign
well
nonmalign
condit
hsct
conduct
unit
state
http
wwwcibmtrorg
two
main
type
hsct
autolog
allogen
autolog
hsct
involv
collect
stem
cell
patient
infus
back
chemotherapi
allogen
hsct
involv
infus
stem
cell
donor
morbid
mortal
hsctrelat
complic
declin
past
sever
year
complic
broadli
categor
base
etiolog
name
whether
infecti
noninfecti
time
onset
complic
earli
vs
late
pulmonari
complic
common
lifethreaten
complic
post
hsct
occur
patient
defin
late
onset
complic
occur
month
posthsct
fig
chapter
discuss
late
noninfecti
pulmonari
complic
hsct
current
concept
pathogenesi
diagnosi
manag
primari
focu
bronchiol
obliteran
bo
common
carri
highest
mortal
late
onset
noninfecti
complic
late
onset
noninfecti
complic
discuss
includ
idiopath
pneumonia
syndrom
organ
pneumonia
pulmonari
venoocclus
diseas
pulmonari
cytolyt
thrombi
pleuroparenchym
fibroelastosi
thorac
air
leak
syndrom
posttranspl
lymphoprolif
disord
clinic
featur
bobo
nonspecif
earli
stage
diseas
patient
asymptomat
identifi
airflow
limit
pft
nonproduct
cough
dyspnea
exert
decreas
exercis
toler
common
physic
examin
may
normal
reveal
sign
airflow
obstruct
wheez
hyperinfl
diffus
crackl
caus
present
particular
respiratori
infect
rule
chest
radiograph
may
normal
reveal
hyperinfl
high
resolut
chest
tomographi
hrct
reveal
small
airway
involv
featur
air
trap
evidenc
mosaic
attenu
expiratori
view
fig
histopatholog
avail
show
narrow
complet
occlus
bronchiolar
lumen
due
subepitheli
inflammatori
fibrosi
hallmark
bo
fig
transbronchi
biopsi
insuffici
yield
diagnosi
surgic
lung
biopsi
often
prohibit
expos
patient
procedur
risk
case
bo
diagnos
without
histopatholog
diagnosi
use
pft
appropri
clinic
set
updat
nation
institut
health
nih
guidelin
diagnos
bo
base
follow
criteria
forc
expiratori
volum
one
second
vital
capac
fifth
percentil
predictedvit
capac
includ
forc
vital
capac
slow
vital
capac
whichev
greaterth
fifth
percentil
predict
lower
limit
confid
intervalfor
pediatr
elderli
patient
use
lower
limit
normal
defin
accord
nation
health
nutrit
examin
survey
iii
calcul
predict
declin
less
year
correct
predict
albuterol
absolut
declin
correct
valu
still
remain
yearsabs
infect
respiratori
tract
document
investig
direct
clinic
symptom
chest
radiograph
comput
tomograph
ct
scan
microbiolog
cultur
sinu
aspir
upper
respiratori
tract
viral
screen
sputum
cultur
bronchoalveolar
lavag
one
two
support
featur
bo
evid
air
trap
expiratori
ct
small
airway
thicken
bronchiectasi
highresolut
chest
ct
orevid
air
trap
pft
residu
volum
predict
residu
volumetot
lung
capac
elev
outsid
confid
interv
import
recogn
signific
number
bronchiol
must
involv
manifest
airflow
limit
pft
develop
clinic
symptom
henc
earli
stage
bo
may
miss
sever
risk
factor
develop
bo
identifi
close
associ
occurr
cgvhd
increas
age
donorrecipi
develop
acut
gvhd
abo
incompat
presenc
extra
thorac
gvhd
low
circul
igg
noncaucasian
race
identifi
sever
retrospect
studi
addit
risk
factor
includ
type
transplant
procedur
peripher
blood
stem
cell
transplant
busulfanbas
condit
regimen
use
antithymocyt
globulin
atg
part
pretranspl
condit
regimen
associ
decreas
incid
ofbo
prior
meet
establish
criteria
bo
decreas
pretranspl
level
also
identifi
risk
factor
subsequ
develop
bo
recent
declin
pretranspl
day
posttranspl
shown
predict
develop
bo
precis
pathogenet
mechan
involv
develop
bo
unclear
pathogenesi
appear
multifactori
may
involv
divers
etiolog
airway
epitheli
injuri
incit
factor
secondari
gastroesophag
reflux
diseas
respiratori
infect
chemotherapeut
drug
typic
follow
dysregul
immun
respons
lead
develop
fibrot
chang
small
airway
cell
humor
mechan
implic
genet
polymorph
link
suscept
bo
current
effect
treatment
forbo
complic
hsct
treatment
protocol
base
combin
immunosuppress
drug
recent
larg
base
expert
opinion
tradit
immunosuppress
form
system
steroid
extend
period
use
altern
calcineurin
inhibitor
azathioprin
agent
impair
lymphocyt
activ
prolifer
employ
longterm
highintens
immunosuppress
longer
recommend
due
increas
risk
infect
clinic
studi
treatment
bo
difficult
interpret
due
small
sampl
size
retrospect
natur
confound
effect
treatment
cgvhd
studi
includ
system
corticosteroid
rituximab
imatinib
etanercept
well
extracorpor
photopheresi
recent
retrospect
match
cohort
studi
recent
show
extracorpor
photopheresi
improv
surviv
hsct
patient
bo
treatment
inhal
budesonideformoterol
led
signific
improv
patient
mildsever
bo
allogen
hsct
anoth
trial
show
stabil
use
combin
fluticason
azithromycin
montelukast
along
puls
dose
system
steroid
random
doubleblind
placebocontrol
trial
azithromycin
alon
reveal
chang
late
bo
post
hsct
prophylact
azithromycin
shown
prevent
onset
lung
bo
well
stabil
fevi
postlung
transplant
bo
howev
prophylact
azithromycin
shown
effect
bo
posthsct
retrospect
studi
prospect
studi
prophylact
use
azithromycin
prevent
airflow
declin
result
earli
termin
secondari
hematolog
relaps
fda
warn
issu
august
review
http
prospect
trial
azithromycin
bortezomib
inhal
cyclosporin
neutrophil
elastas
inhibitor
prophylaxi
andor
treatment
bo
underway
wwwclinicaltrialsgov
current
treatment
strategi
includ
highdos
inhal
glucocorticoid
without
long
act
inhal
beta
agonist
base
symptom
close
monitor
lung
function
pft
progress
declin
occur
regimen
initi
combin
fluticason
azithromycin
montelukast
fam
therapi
consid
occasion
patient
chronic
gvhd
refractori
bo
may
respond
increas
immunosuppress
patient
progress
despit
medic
therapi
lung
transplant
may
option
novel
therapeut
approach
bobo
current
investig
pleiotrop
small
molecul
mak
inhibitor
pirfenidon
shown
amelior
bo
murin
model
cgvhd
earli
phase
clinic
studi
evalu
safeti
toler
pirfenidon
bo
current
underway
wwwclinicaltrialsgov
clinic
cours
ofbo
variabl
patient
experienc
rapid
declin
lung
function
other
stabil
improv
mortal
bo
commonli
due
progress
respiratori
failur
bo
confer
fold
increas
risk
death
diagnosi
earli
onset
bo
lower
fvc
especi
within
year
transplant
associ
wors
prognosi
recent
estim
indic
year
surviv
surviv
improv
overal
surviv
decad
ago
surviv
surviv
earli
recognit
newer
treatment
strategi
better
support
care
like
account
improv
surviv
although
exact
caus
ip
remain
unknown
immun
involv
invok
murin
model
involv
immun
mismatch
donor
recipi
support
concept
elev
level
lipopolysaccharid
lp
tumor
necrosi
factoralpha
observ
bal
sampl
murin
ip
model
may
contribut
pathogenesi
direct
toxic
upregul
major
histocompat
complex
mhc
increas
leukocyt
recruit
cellmedi
apoptosi
donor
lymphocyt
secret
chemokin
amplifi
inflammatori
cascad
decreas
level
pulmonari
surfact
also
associ
ip
develop
risk
factor
ip
includ
fullintens
condit
regimen
total
bodi
irradi
busulfan
acut
gvhd
advanc
age
underli
acut
leukemia
myelodysplast
syndrom
md
reducedintens
condit
regimen
decreas
incid
ip
children
risk
factor
ip
includ
underli
diseas
busulfanbas
condit
regimen
interestingli
risk
ip
increas
number
platelet
transfus
receiv
though
transfus
requir
could
marker
diseas
sever
definit
ip
updat
american
thorac
societi
guidelin
base
follow
criteria
evid
widespread
alveolar
injurymultilobar
infiltr
routin
chest
radiograph
comput
tomographysymptom
sign
pneumonia
cough
dyspnea
tachypnea
rale
evid
abnorm
pulmonari
physiolog
increas
alveolar
arteri
oxygen
differ
ii
new
increas
restrict
pulmonari
function
test
abnormalityabs
activ
lower
respiratori
tract
infect
base
upon
bronchoalveolar
lavag
neg
signific
bacteri
pathogen
includ
acidfast
bacilli
nocardia
legionella
speciesbronchoalveolar
lavag
neg
pathogen
nonbacteri
microorgan
routin
cultur
virus
fungi
ii
shell
vial
cultur
cmv
respiratori
rsv
iii
cytolog
cmv
inclus
fungi
pneumocysti
jirovecii
carinii
iv
direct
fluoresc
stain
antibodi
cmv
rsv
hsv
vzv
influenza
viru
parainfluenza
viru
adenoviru
organismsoth
organismstest
also
consid
polymeras
chain
reaction
human
metapneumoviru
rhinoviru
coronaviru
ii
polymeras
chain
reaction
chlamydia
mycoplasma
aspergillu
speci
iii
serum
galactomannan
elisa
aspergillu
speciestransbronchi
biopsi
condit
patient
permitsabs
cardiac
dysfunct
acut
renal
failur
iatrogen
fluid
overload
etiolog
pulmonari
dysfunct
radiograph
find
nonspecif
hrct
find
includ
ground
glass
opac
bilater
central
symmetr
consolid
seen
sever
case
recent
advanc
diagnost
capabl
increas
detect
occult
infect
help
separ
ip
infecti
hsct
complic
distinct
critic
due
vastli
distinct
treatment
approach
mani
patient
diagnos
ip
later
discov
detect
pathogen
commonli
human
rhinoviru
aspergillu
bal
sampl
reexamin
histor
treatment
ip
larg
support
infect
rule
system
corticosteroid
mainstay
treatment
ip
associ
diffus
alveolar
hemorrhag
may
requir
higher
dose
result
immunotherapeut
agent
solubl
inhibitor
etanercept
mix
retrospect
singlecent
studi
two
distinct
timeperiod
compar
steroid
alon
earlier
timeperiod
versu
combin
steroid
etanercept
show
signific
improv
surviv
hospit
discharg
howev
recent
use
reducedintens
condit
regimen
improv
support
care
may
account
improv
patient
lateonset
ip
respond
etanercept
greatli
improv
short
longterm
mortal
result
children
similarli
promis
complet
respons
patient
random
doubleblind
placebocontrol
trial
compar
corticosteroid
placebo
corticosteroid
etanercept
inconclus
due
slow
patient
accrual
earli
termin
potenti
therapi
investig
blockad
transcript
factor
downstream
receptor
shown
promis
murin
model
pulmonari
surfact
replac
also
studi
intervent
treat
ip
outcom
ip
remain
poor
mortal
rate
rapid
clinic
deterior
occur
patient
requir
mechan
ventil
succumb
diseas
venoven
extracorpor
membran
oxygen
ecmo
rescu
therapi
bridgetorecoveri
met
mix
result
shortterm
surviv
improv
treatment
advanc
surviv
remain
low
base
small
studi
rapid
peak
declin
sever
infiltr
hrct
link
favor
prognosi
biomark
predict
patient
risk
ip
respond
biolog
therapi
studi
op
present
fever
nonproduct
cough
dyspnea
precipit
recent
taper
immunosuppress
regimen
pft
commonli
reveal
restrict
pattern
could
normal
obstruct
mix
decreas
diffus
capac
carbon
monoxid
dlco
high
resolut
chest
tomograph
scan
patient
op
notabl
airspac
consolid
ground
glass
opac
nodular
opac
fig
studi
patient
biopsyproven
op
posthsct
ground
glass
opac
note
common
radiolog
featur
bronchoalveolar
lavag
use
exclud
infect
surgic
lung
biopsi
gold
standard
diagnosi
op
transbronchi
biopsi
lower
yield
howev
latter
approach
may
use
certain
clinic
set
histopatholog
featur
biopsi
includ
presenc
bud
granul
tissu
contain
myofibroblast
loos
connect
tissu
fig
bud
intraalveolar
extend
bronchiol
caus
obstruct
associ
mild
interstiti
inflamm
prior
histori
acut
chronic
gvhd
found
strong
risk
factor
op
suggest
common
pathogenesi
studi
patient
postallogen
hcst
recipi
hla
dispar
femaletomal
hsct
peripher
blood
stem
cell
transplant
pbsct
associ
increas
risk
develop
op
contrast
busulfanbas
fludarabinebas
reducedintens
condit
compar
total
bodi
irradi
cell
deplet
regimen
associ
lower
risk
precis
pathogenet
mechan
posthsct
op
unclear
associ
gvhd
increas
incid
postallogen
hsct
suggest
alloimmunemedi
lung
injuri
murin
model
op
respiratori
reoviru
infect
demonstr
role
cell
cytokin
develop
process
hsctassoci
op
case
op
primarili
treat
highdos
system
corticosteroid
specif
guidelin
dose
durat
steroid
therapi
current
recommend
base
expert
opinion
clinic
judgment
exercis
prednison
dose
rang
mgkgday
use
month
slow
taper
month
studi
need
establish
ideal
dose
durat
corticosteroid
therapi
erythromycin
combin
corticosteroid
report
favor
outcom
although
role
macrolid
treatment
op
unclear
patient
hsctassoci
op
favor
prognosi
resolut
stabil
corticosteroid
therapi
clinic
improv
seen
usual
within
week
start
therapi
follow
radiolog
improv
failur
respond
treatment
may
result
progress
respiratori
failur
death
present
complaint
usual
nonspecif
primarili
fatigu
exert
dyspnea
physic
examin
find
similar
pulmonari
hypertens
may
normal
earli
stage
becom
appar
later
stage
elev
jvd
peripher
edema
hepatomegali
elev
second
heart
sound
parastern
lift
palpabl
second
heart
sound
second
left
intercost
space
recogn
patient
along
tricuspid
regurgit
murmur
comput
tomograph
ct
scan
chest
may
show
septal
thicken
diffus
mosaic
ground
glass
opac
small
nodul
area
consolid
right
heart
catheter
reveal
increas
pulmonari
arteri
pressur
normal
pulmonari
capillari
pressur
triad
sever
pulmonari
hypertens
set
normal
pulmonari
arteri
occlus
pressur
radiograph
evid
pulmonari
edema
could
suggest
pvod
diagnost
pvod
definit
diagnos
surgic
biopsi
character
progress
intim
prolifer
fibrosi
occlus
pulmonari
venul
well
small
vein
pathogenesi
pvod
post
hsct
unclear
attribut
toxic
endotheli
injuri
secondari
chemotherapeut
condit
regimen
andor
viral
infect
seem
associ
cgvhd
effect
treatment
pvod
prognosi
poor
convent
arteri
vasodil
therapi
pulmonari
hypertens
could
worsen
pulmonari
edema
pvod
initi
done
close
monitor
report
case
pvod
post
hsct
shown
favor
respons
steroid
therapi
pulmonari
cytolyt
thrombi
pct
complic
allogen
hsct
primarili
occur
children
gvhd
incid
median
onset
month
post
hsct
patient
typic
present
fever
cough
dyspnea
ct
scan
chest
show
peripher
pulmonari
pleural
nodul
bronchoalveolar
lavag
indic
exclud
infecti
etiolog
diagnosi
pct
base
surgic
biopsi
lung
nodul
character
vascular
occlus
hemorrhag
infarct
secondari
thrombi
contain
intens
basophil
amorph
materi
well
entrap
leucocyt
prognosi
pct
favor
respond
treatment
system
corticosteroid
mortal
attribut
pct
report
literatur
pleuroparenchym
fibroelastosi
ppfe
rare
complic
hsct
group
rare
interstiti
pneumonia
preval
around
hsct
recipi
character
progress
sub
pleural
fibrosi
predominantli
upper
lobe
ppfe
report
post
allogen
autolog
hsct
etiolog
ppfe
post
hsct
unclear
chemotherapeut
drug
radiat
therapi
possibl
associ
cgvhd
hypothes
predispos
factor
patient
present
dri
cough
exert
dyspnea
chest
pain
secondari
spontan
pneumothorax
pft
reveal
restrict
mix
pictur
obstruct
restrict
ct
scan
characterist
pleural
thicken
fibrosi
subpleur
reticul
traction
bronchiectasi
predominantli
upper
lobe
histopatholog
exam
reveal
alveolar
collaps
subpleur
fibrosi
extens
elast
deposit
diseas
progress
worsen
symptom
poor
prognosi
current
therapeut
option
avail
except
lung
transplant
thorac
air
leak
syndrom
tal
consist
spectrum
condit
includ
spontan
pneumothorax
subcutan
emphysema
pneumomediastinum
interstiti
emphysema
pneumopericardium
occur
late
onset
complic
allogen
hsct
associ
cgvhd
accord
report
literatur
preval
tal
post
allogen
hsct
report
median
time
rang
day
post
hsct
mechan
air
leak
bo
secondari
increas
intraalveolar
pressur
lead
alveolar
ruptur
pulmonari
interstitium
subsequ
retrograd
dissect
air
mediastinum
subcutan
tissu
caus
pneumomediastinum
subcutan
emphysema
similarli
ruptur
pleural
space
caus
pneumothorax
ct
scan
chest
imag
modal
choic
detect
air
pleural
space
mediastinum
subcutan
tissu
infect
cough
emesi
caus
similar
present
rule
prognosi
poor
surviv
respect
posttranspl
lymphoprolif
disord
ptld
rare
complic
follow
allogen
hsct
cumul
incid
studi
hsct
patient
risk
factor
unrel
hla
mismatch
donor
use
atg
monoclon
antibodi
cell
gvhd
prophylaxi
treatment
cell
deplet
donor
marrow
age
year
second
hsct
identifi
incid
ptld
rang
patient
risk
factor
risk
factor
pathogenesi
post
hsct
ptld
attribut
prolifer
donor
viru
ebv
infect
b
cell
set
weaken
tcell
immun
though
post
hsct
common
lymph
node
spleen
liver
pulmonari
involv
occur
case
median
onset
around
month
post
hsct
clinic
present
vari
could
rang
asymptomat
fulmin
tumor
lysi
syndrom
ct
scan
chest
notabl
multipl
pulmonari
nodul
basal
peripher
predomin
mediastin
hilar
lymphadenopathi
patchi
consolid
pleural
effus
chest
wall
pleuralbas
mass
diagnosi
may
requir
biopsi
could
made
via
noninvas
method
appropri
clinic
set
probabl
diagnosi
made
increas
ebv
dna
level
set
lymphadenopathi
hepatosplenomegali
caus
rule
proven
diseas
requir
biopsi
treatment
strategi
includ
rituximab
reduct
immunosuppress
donor
lymphocyt
infus
chemotherapi
ebvspecif
cytotox
lymphocyt
infus
prognosi
ptld
post
hsct
poor
compar
occur
solid
organ
transplant
late
onset
pulmonari
complic
follow
hsct
major
caus
mortal
morbid
advanc
transplant
techniqu
earlier
diagnosi
prevent
manag
infecti
complic
led
better
outcom
well
shift
focu
late
noninfecti
pulmonari
complic
hsct
complic
myriad
requir
studi
develop
effect
screen
prevent
treatment
strategi
